Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

RNAZ

TransCode Therapeutics Inc

Apr 23 • 04:00PM ET

0.4599

Dollar change +0.0009
Percentage change 0.20	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-472.87	Insider Own	0.53%	Shs Outstand	6.57M	Perf Week	-8.93%
Market Cap	3.02M	Forward P/E	-	EPS next Y	-0.67	Insider Trans	0.00%	Shs Float	6.54M	Perf Month	-30.98%
Income	-18.55M	PEG	-	EPS next Q	-0.70	Inst Own	0.24%	Short Float	0.61%	Perf Quarter	-41.45%
Sales	0.00M	P/S	-	EPS this Y	97.93%	Inst Trans	-2.22%	Short Ratio	0.07	Perf Half Y	-96.93%
Book/sh	2.62	P/B	0.18	EPS next Y	68.69%	ROA	-290.74%	Short Interest	0.04M	Perf Year	-99.84%
Cash/sh	0.42	P/C	1.09	EPS next 5Y	-	ROE	-759.85%	52W Range	0.42 - 356.00	Perf YTD	-93.02%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-28.81%	ROI	-1104.52%	52W High	-99.87%	Beta	-0.23
Dividend TTM	-	Quick Ratio	1.28	Sales past 5Y	0.00%	Gross Margin	-	52W Low	9.24%	ATR (14)	0.06
Dividend Ex-Date	-	Current Ratio	1.28	EPS Y/Y TTM	56.33%	Oper. Margin	0.00%	RSI (14)	21.64	Volatility	9.61% 8.38%
Employees	10	Debt/Eq	0.27	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	3.00
Option/Short	No / Yes	LT Debt/Eq	0.02	EPS Q/Q	97.94%	Payout	-	Rel Volume	0.16	Prev Close	0.46
Sales Surprise	-	EPS Surprise	-125.93%	Sales Q/Q	-	Earnings	Apr 01 BMO	Avg Volume	604.37K	Price	0.46
SMA20	-24.78%	SMA50	-30.07%	SMA200	-98.11%	Trades		Volume	98,964	Change	0.20%

Apr-15-24 09:00AM	TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors (GlobeNewswire) -13.68%
Apr-03-24 09:10AM	TransCode Therapeutics Reports 2023 Results; Provides Business Update (GlobeNewswire)
Mar-28-24 08:30AM	TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer (GlobeNewswire)
Mar-11-24 09:00AM	TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment (GlobeNewswire) -8.60%
Mar-06-24 04:15PM	TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress (GlobeNewswire)
08:00AM	Loading…
Feb-20-24 08:00AM	TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode's RIG-I Agonist Immunotherapeutic (GlobeNewswire)
Jan-31-24 04:05PM	Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders' Equity Requirement and Continued Listing on The Nasdaq Stock Market (GlobeNewswire) -7.25%
Jan-29-24 08:30AM	TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer (GlobeNewswire)
Jan-22-24 04:45PM	TransCode Therapeutics Announces Closing of $7.25 Million Public Offering (GlobeNewswire)
Jan-19-24 01:09PM	TransCode (RNAZ) Down 50% on Issue of New Common Stock (Zacks) -25.22%
Jan-18-24 01:27PM	TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering (GlobeNewswire) -49.54%
Jan-12-24 04:05PM	TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO (GlobeNewswire) -8.09%
Jan-11-24 08:00AM	TransCode Therapeutics Announces 1-for-40 Reverse Stock Split (GlobeNewswire) +10.57%
Jan-04-24 08:05AM	TransCode Therapeutics Publishes Open Letter Outlining Company's Progress and Objectives (GlobeNewswire) -8.18%
Dec-12-23 08:30AM	TransCode Therapeutics Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138 (GlobeNewswire) -9.38%
09:00AM	Loading…
Dec-05-23 09:00AM	TransCode Therapeutics To Present Phase 0 Data at 2023 San Antonio Breast Cancer Symposium (GlobeNewswire)
Dec-04-23 04:10PM	TransCode Therapeutics Announces Closing of $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules (GlobeNewswire)
Nov-30-23 02:53PM	TransCode Therapeutics Announces $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules (GlobeNewswire)
Nov-14-23 04:30PM	TransCode Therapeutics Reports Third Quarter 2023 Results; Provides Business Update (GlobeNewswire)
Oct-30-23 04:33PM	TransCode Therapeutics Withdraws Public Offering (GlobeNewswire) +10.36%
Oct-27-23 08:16AM	Why Is TransCode Therapeutics (RNAZ) Stock Down 25% Today? (InvestorPlace) -21.61%
08:00AM	Nasdaq Panel Grants TransCode Therapeutics Extension for Continued Listing on The Nasdaq Stock Market Subject to Conditions (GlobeNewswire)
Oct-26-23 04:19PM	TransCode Therapeutics Announces Public Offering of Common Stock (GlobeNewswire) +12.13%
08:00AM	TransCode Therapeutics Announces Prolonged Survival in Murine Models with Glioblastoma Treated with Its Lead Candidate, TTX-MC138 (GlobeNewswire)
Oct-24-23 08:00AM	TransCode Therapeutics Announces Preliminary Clinical Results in First Patient in Phase 0 Clinical Study with Lead Therapeutic Candidate, TTX-MC138 (GlobeNewswire) +40.39%
Oct-16-23 08:00AM	TransCode Therapeutics Reports Successful Treatment of Preclinical Melanoma Tumors with its Immunotherapy Candidate, TTX-RIGA (GlobeNewswire) +5.84%
Sep-28-23 04:02PM	TransCode Therapeutics Announces Closing of $8.5 Million Public Offering (GlobeNewswire)
Sep-25-23 08:01PM	TransCode Therapeutics Announces Pricing of $8 Million Public Offering (GlobeNewswire) +284.04%
08:30AM	TransCode Therapeutics Announces Positive Pre-Clinical Glioblastoma Results with Lead Therapeutic Candidate, TTX-MC138 (GlobeNewswire)
Aug-23-23 08:00AM	TransCode Therapeutics Announces First Subject Dosed with Radiolabeled TTX-MC138 in First-In-Human Clinical Trial (GlobeNewswire)
04:45PM	Loading…
Aug-14-23 04:45PM	TransCode Therapeutics Reports Second Quarter 2023 Results; Provides Business Update (GlobeNewswire)
Jul-31-23 07:00AM	TransCode Therapeutics Announces Positive Results in Non-human Primates with its Lead Therapeutic Candidate, TTX-MC138 (GlobeNewswire) -5.17%
Jul-13-23 12:43PM	Stonegate Healthcare Partners Announces Publishing of a Thematic Report - The RNA Revolution: Unleashing the Therapeutic Potential of RNAi (Newsfile) -6.71%
Jul-10-23 09:55AM	TransCode Therapeutics Inc. (RNAZ) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Jul-05-23 07:00AM	TransCode Therapeutics CEO Letter to Shareholders (GlobeNewswire)
Jun-28-23 03:49PM	TransCode Therapeutics making preclinical progress with lead metastatic cancer candidate (News Direct)
Jun-23-23 09:24AM	Daily Vickers Top Buyers & Sellers for 06/23/2023 (Argus Research)
Jun-22-23 07:00AM	TransCode Therapeutics Announces Publication of New Data Supporting the Use of TTX-MC138 for the Treatment of Metastatic Breast Cancer (GlobeNewswire) -7.75%
Jun-09-23 04:05PM	TransCode Therapeutics Announces Closing of $7 Million Public Offering (GlobeNewswire)
Jun-07-23 11:00AM	Why TransCode Therapeutics Stock Is Trading Higher Premarket Today (Benzinga)
Jun-06-23 05:29PM	TransCode Therapeutics Announces Pricing of $7 Million Public Offering (GlobeNewswire) -19.75%
04:01PM	TransCode Therapeutics Reports Positive Preclinical Results with its Lead Candidate, TTX-MC138, in Glioblastoma (GlobeNewswire)
May-22-23 07:00AM	TransCode Therapeutics Announces 1-for-20 Reverse Stock Split (GlobeNewswire) -5.38%
Apr-27-23 07:00AM	TransCode Therapeutics Announces IRB Approval for FDA Cleared First-In-Human Clinical Trial (GlobeNewswire) -9.65%
Apr-26-23 08:00AM	TransCode Therapeutics Announces Strategic Expansion of its Product Portfolio (GlobeNewswire)
Apr-14-23 07:00AM	TransCode Therapeutics Announces Equity Investment from White Lion Capital to Help Fund Development of TTX-MC138 for Treatment of Glioblastomas (GlobeNewswire)
Apr-06-23 07:00AM	TransCode Therapeutics to present at AACR Annual Meeting 2023 (GlobeNewswire) -14.90%
Apr-05-23 07:00AM	TransCode Therapeutics Receives Notice of Award from National Institutes of Health (NIH) for Third Year of Grant to Support Clinical Evaluation of TTX-MC138 (GlobeNewswire) +31.52%
Apr-04-23 09:00PM	TransCode Therapeutics Announces Termination of Previously Announced Sale of Series A Preferred Stock (GlobeNewswire) -5.54%
Apr-03-23 08:00AM	TransCode Therapeutics Announces Agreement with Triton Funds for Sale of Series A Convertible Preferred Stock (GlobeNewswire)
Mar-31-23 04:01PM	TransCode Therapeutics Reports 2022 Results; Provides Business Update (GlobeNewswire)
Feb-28-23 07:00AM	TransCode Therapeutics Announces Orphan Drug Designation Status for TTX-MC138 for Treatment of Pancreatic Cancer (GlobeNewswire) +9.04%
Feb-22-23 08:00AM	TransCode Therapeutics and BRAIN Biotech join forces to develop a CRISPR-derived technology platform for cancer treatment (GlobeNewswire)
Feb-18-23 08:42AM	Great news for TransCode Therapeutics, Inc. (NASDAQ:RNAZ): Insiders acquired stock in large numbers last year (Simply Wall St.)
Feb-17-23 04:10PM	TransCode Therapeutics Announces Closing of $1.5 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules (GlobeNewswire)
Feb-16-23 08:00AM	TransCode Therapeutics Announces $1.5 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules (GlobeNewswire) -24.73%
Feb-01-23 07:49AM	Why TransCode Therapeutics (RNAZ) Shares Are Trading Higher Today (Benzinga) +16.01%
Jan-31-23 04:05PM	TransCode Therapeutics Reports Positive Preclinical Results with its Immunotherapy Candidate, TTX-RIGA, in Melanoma (GlobeNewswire) -17.49%
Dec-29-22 09:34AM	FDA Authorizes TransCode's First-In-Human Clinical Trial With Solid Tumor Patients (Benzinga) -6.54%
08:00AM	TransCode Therapeutics Announces FDA Authorization to Proceed with First-In-Human Clinical Trial (GlobeNewswire)
Dec-07-22 02:37PM	Small Biotechs Are Pulling Public Offerings, IPOs Amid 'Current Market Conditions' (Benzinga) +133.44%
Dec-06-22 04:20PM	TransCode Therapeutics Announces Withdrawal of Registration Statement (GlobeNewswire)
Nov-30-22 07:00AM	TransCode Therapeutics Announces eIND Submission to US FDA for Planned First-in-Human Clinical Trial in Patients with Advanced Solid Tumors (GlobeNewswire) -6.76%
Nov-14-22 04:15PM	TransCode Therapeutics Reports Third Quarter 2022 Results; Provides Business Update (GlobeNewswire)
Nov-09-22 07:00AM	TransCode Therapeutics Reports Positive Preclinical Results with its Immunotherapy Candidate, TTX-siPDL1, in Pancreatic Adenocarcinoma (GlobeNewswire) -14.24%
Nov-08-22 03:40PM	Sidoti's November Micro-Cap Virtual Conference (ACCESSWIRE)
Nov-07-22 08:00AM	TransCode Therapeutics to Present at Sidoti Virtual Investor Conference (GlobeNewswire)
Oct-26-22 10:51AM	TransCode Therapeutics Shares Shoot Higher After Encouraging Preclinical Data From Lead Cancer Candidate (Benzinga) +6.48%
07:00AM	TransCode Therapeutics Reports Positive Preclinical Results with its Lead Candidate, TTX-MC138, in Pancreatic Adenocarcinoma (GlobeNewswire)
Oct-19-22 08:00AM	TransCode Therapeutics: Invitation to The ThinkEquity Conference (Newsfile) -5.69%
Oct-13-22 07:00AM	TransCode Therapeutics Announces Publication of Feline Case Study in Frontiers in Oncology (GlobeNewswire)
Sep-27-22 08:00AM	TransCode Therapeutics to Participate at the Chardan 6th Annual Genetic Medicines Conference (GlobeNewswire)
Sep-08-22 08:00AM	TransCode Therapeutics Appoints MicroRNA Pioneer, Dr. Frank Slack, to its Advisory Board (GlobeNewswire) +7.69%
Aug-15-22 04:15PM	TransCode Therapeutics Reports Second Quarter 2022 Results; Provides Business Update (GlobeNewswire)
Aug-02-22 07:00AM	TransCode Therapeutics and MD Anderson Announce Strategic Alliance to Advance RNA Therapies for Oncology (GlobeNewswire)
Jul-11-22 04:05PM	TransCode Therapeutics Announces Expansion of Global RNA Oncology Patent Portfolio (GlobeNewswire)
Jul-04-22 03:13PM	A number of insiders bought TransCode Therapeutics, Inc. (NASDAQ:RNAZ) stock last year, which is great news for shareholders (Simply Wall St.)
Jun-09-22 09:00AM	TransCode Therapeutics to Participate at BIO International Convention (GlobeNewswire)
Jun-01-22 09:00AM	TransCode Therapeutics Receives National Institutes of Health (NIH) Notice of Award (GlobeNewswire)
May-20-22 09:00AM	TransCode Therapeutics To Participate at H.C. Wainwright Global Investment Conference (GlobeNewswire)
May-19-22 09:00AM	TransCode Therapeutics Acquires Option for Radiotheranostic Technology (GlobeNewswire)
May-16-22 08:30AM	TransCode Therapeutics Reports First Quarter 2022 Results; Provides Business Update (GlobeNewswire) -8.00%
Apr-13-22 09:00AM	TransCode Therapeutics CTO, Dr. Zdravka Medarova, to Moderate 7th Annual RNA Medicine Symposium (GlobeNewswire)
Apr-05-22 07:17AM	Dolby's (DLB) Transcode API to Speed Up Workflow Creation (Zacks)
Mar-31-22 04:30PM	TransCode Therapeutics Reports 2021 Results; Provides Business Update (GlobeNewswire) +5.49%
Mar-25-22 12:00PM	TransCode Therapeutics Interview to Air on Bloomberg U.S. on the RedChip Money Report® (GlobeNewswire) -5.38%
Mar-23-22 09:00AM	TransCode Therapeutics Announces Article Published in the Journal Cancers Detailing the Potential for Short RNA-based Drugs in Cancer and a Broad Range of Disorders (GlobeNewswire)
Feb-14-22 09:00AM	TransCode Therapeutics Announces Expansion of Global RNA Oncology Patent Portfolio (GlobeNewswire)
Feb-10-22 09:46AM	CORRECTION --TransCode Therapeutics (GlobeNewswire)
08:30AM	TransCode Therapeutics to Present at 2020 BIO CEO & INVESTOR CONFERENCE (GlobeNewswire)
Jan-06-22 03:17PM	TransCode Therapeutics To Participate at H.C. Wainwright BioConnect Conference (GlobeNewswire)
Dec-06-21 07:10PM	TransCode Therapeutics To Participate at MedInvest Oncology Investor Conference (GlobeNewswire)
Nov-18-21 10:57AM	Companies Like TransCode Therapeutics (NASDAQ:RNAZ) Are In A Position To Invest In Growth (Simply Wall St.) -6.25%
Nov-15-21 04:01PM	TransCode Therapeutics Reports Business Progress and Third Quarter 2021 Financial Results (Business Wire)
Nov-09-21 07:30AM	TransCode Therapeutics Announces Participation in the Q4 Virtual Investor Summit (Newsfile) -7.95%
Sep-30-21 04:01PM	TransCode Therapeutics Appoints Zdravka Medarova, Ph.D., as Chief Technology Officer (Business Wire) -5.08%
Sep-23-21 11:05AM	Why Are TransCode Therapeutics Shares Shooting Higher On Thursday? (Benzinga) +53.44%
07:30AM	TransCode Therapeutics Announces Publication in Cancer Nanotechnology of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Metastatic Breast Cancer (Business Wire)
Aug-23-21 04:01PM	TransCode Therapeutics Reports Business Progress and Second Quarter 2021 Financial Results (Business Wire)
Aug-05-21 07:30AM	TransCode Therapeutics Awarded Funding from National Institutes of Health (NIH) to Support Clinical Evaluation of TTX-MC138 (Business Wire)

TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company was founded by Robert Michael Dudley, Zdravka Medarova, and Anna Moore in January 2016 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Dudley Robert Michael	Chief Executive Officer	Sep 28 '23	Buy	0.51	98,000	49,980	180,262	Oct 02 04:37 PM
Fitzgerald Thomas A	Chief Financial Officer	Sep 28 '23	Buy	0.51	49,350	25,168	56,318	Oct 02 04:39 PM
Dudley Robert Michael	Chief Executive Officer	Jun 21 '23	Buy	2.65	12,000	31,818	82,262	Jun 22 06:23 PM
Dudley Robert Michael	Chief Executive Officer	Jun 20 '23	Buy	2.55	6,607	16,847	70,262	Jun 22 06:23 PM
Dudley Robert Michael	Chief Executive Officer	Jun 09 '23	Buy	2.76	19,000	52,440	912,114	Jun 13 04:16 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RNAZ

TransCode Therapeutics Inc

Upgrade your FINVIZ experience